Publication:
What we learned about COVID-19 so far? Notes from underground

dc.contributor.buuauthorGünaydın, Fatma Esra
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentGöğüs Hastalıkları Ana Bilim Dalı
dc.contributor.researcheridHKV-2265-2023
dc.contributor.scopusid57210113218
dc.date.accessioned2023-10-16T10:34:01Z
dc.date.available2023-10-16T10:34:01Z
dc.date.issued2020-05
dc.descriptionÇalışmada 36 yazar bulunmaktadır. Bu yazarlardan Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.
dc.description.abstractThe novel coronavirus pandemic poses a major global threat to public health. Our knowledge concerning every aspect of COVID-19 is evolving rapidly, given the increasing data from all over the world. In this narrative review, the Turkish Thoracic Society Early Career Taskforce members aimed to provide a summary on recent literature regarding epidemiology, clinical findings, diagnosis, treatment, prevention, and control of COVID-19. Studies revealed that the genetic sequence of the novel coronavirus showed significant identity to SARS-CoV and MERS-CoV. Angiotensin-converting enzyme 2 receptor is an important target of the SARS-CoV-2 while entering an organism. Smokers were more likely to develop the disease and have a higher risk for ICU admission. The mean incubation period was 6.4 days, whereas asymptomatic transmission was reported up to 25 days after infection. Fever and cough were the most common symptoms, and cardiovascular diseases and hypertension were reported to be the most common comorbidities among patients. Clinical manifestations range from asymptomatic and mild disease to severe acute respiratory distress syndrome. Several patients showed typical symptoms and radiological changes with negative RT-PCR but positive IgG and IgM antibodies. Although radiological findings may vary, bilateral, peripherally distributed, ground-glass opacities were typical of COVID-19. Poor prognosis was associated with older age, higher Sequential Organ Failure Assessment score, and high D-dimer level. Chloroquine was found to be effective in reducing viral replication in vitro. Likewise, protease inhibitors, including lopinavir/ritonavir, favipiravir, and nucleoside analogue remdesivir were proposed to be the potential drug candidates in COVID-19 management. Despite these efforts, we still have much to learn regarding the transmission, treatment, and prevention of COVID-19.
dc.description.sponsorshipTürk Toraks Derneği
dc.description.sponsorshipTTS Early Career Members Taskforce Group
dc.identifier.citationGünaydın, F. E. vd. (2020). "What we learned about COVID-19 so far? Notes from underground". Turkish Thoracic Journal, 21(3), 185-192.
dc.identifier.endpage192
dc.identifier.issn2149-2530
dc.identifier.issue3
dc.identifier.pubmed32584236
dc.identifier.scopus2-s2.0-85086933171
dc.identifier.startpage185
dc.identifier.urihttps://doi.org/10.5152/TurkThoracJ.2020.20052
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311152/
dc.identifier.urihttp://hdl.handle.net/11452/34377
dc.identifier.volume21
dc.identifier.wos000540904400009
dc.indexed.trdizinTrDizin
dc.indexed.wosESCI
dc.language.isoen
dc.publisherAVES
dc.relation.collaborationYurt içi
dc.relation.collaborationSanayi
dc.relation.journalTurkish Thoracic Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectReal-time PCR
dc.subjectHydroxychloroquine
dc.subjectSARS-CoV-2
dc.subjectRespiratory system
dc.subject.emtreeAngiotensin converting enzyme 2
dc.subject.emtreeArbidol
dc.subject.emtreeBortezomib
dc.subject.emtreeC reactive protein
dc.subject.emtreeCarfilzomib
dc.subject.emtreeChloroquine
dc.subject.emtreeD dimer
dc.subject.emtreeFavipiravir
dc.subject.emtreeFerritin
dc.subject.emtreeHydroxychloroquine
dc.subject.emtreeImatinib
dc.subject.emtreeImmunoglobulin G antibody
dc.subject.emtreeImmunoglobulin M antibody
dc.subject.emtreeLopinavir plus ritonavir
dc.subject.emtreeRemdesivir
dc.subject.emtreeTeicoplanin
dc.subject.emtreeAdult respiratory distress syndrome
dc.subject.emtreeAerosol
dc.subject.emtreeAntihypertensive therapy
dc.subject.emtreeArticle
dc.subject.emtreeArtificial ventilation
dc.subject.emtreeAsymptomatic infection
dc.subject.emtreeBlood group typing
dc.subject.emtreeBronchoscopy
dc.subject.emtreeComputer assisted tomography
dc.subject.emtreeCoronavirus disease 2019
dc.subject.emtreeCoughing
dc.subject.emtreeDisease transmission
dc.subject.emtreeGastrointestinal symptom
dc.subject.emtreeGene sequence
dc.subject.emtreeHeadache
dc.subject.emtreeHigh risk patient
dc.subject.emtreeHuman
dc.subject.emtreeInfluenza
dc.subject.emtreeLung ventilation
dc.subject.emtreeMixed infection
dc.subject.emtreeMortality
dc.subject.emtreeMyalgia
dc.subject.emtreePediatric patient
dc.subject.emtreeRenin angiotensin aldosterone system
dc.subject.emtreeReverse transcription polymerase chain reaction
dc.subject.emtreeRhinorrhea
dc.subject.emtreeSeasonal variation
dc.subject.emtreeSequential organ failure assessment score
dc.subject.emtreeSmoking
dc.subject.emtreeSore throat
dc.subject.emtreeThorax radiography
dc.subject.emtreeVirus load
dc.subject.emtreeVirus replication
dc.subject.emtreeVirus shedding
dc.subject.emtreeVirus transmission
dc.subject.scopusRadiological findings; Clinical features; COVID-19
dc.subject.wosRespiratory system
dc.titleWhat we learned about COVID-19 so far? Notes from underground
dc.typeReview
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Göğüs Hastalıkları Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atScopus
local.indexed.atWOS

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Günaydın_vd_2020.pdf
Size:
575.93 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: